AI Article Synopsis

  • The study analyzed 1,500 adverse reaction cases related to Guizhi Fuling Capsules from 2008 to 2017 using different statistical methods.
  • The number of reports increased over time, peaking in late 2014, with the majority of cases (62.27%) involving patients aged 18-44, and common reactions including gastric dysfunction and abdominal pain.
  • The study identified early warning signs for adverse reactions, confirming that while the capsules have fewer side effects, vigilance and risk management are still essential.

Article Abstract

To understand the characteristics of adverse reactions and find early warning signs after intake of Guizhi Fuling Capsules. The 1 500 adverse reaction(ADR) cases of Guizhi Fuling Capsules obtained by spontaneous reporting system(SRS) from 2008 to 2017 were analyzed by proportional reporting ratios method(PRR), Bayesian confidence propagation neural network method(BCPNN) and propensity score method. The number of ADR reports increased year by year, and reached the peak in the fourth quarter of 2014. A total of 1 500 ADR cases were monitored, including 10 severe ADR cases. There were a total of 934 cases aged between 18-44 years old, accounting for 62.27%. All patients were orally administered. Among them, 1 398 patients received a single dose according to the package insert, and 57.4% had ADR within 24 h. The top five clinical manifestations of ADR were gastric dysfunction, abdominal pain, nausea, vomiting and rash, which mainly damaged the digestive system. The ADR signals were analyzed. PRR suggested that "gastric dysfunction" and "abdominal pain" were the early warning signals of Guizhi Fuling Capsules. BCPNN suggested that "nausea" and "abdominal pain" were the early warning signals of Guizhi Fuling Capsules. After the propensity score weighting method was used to control the confounding factors, the warning signals remained unchanged. The results show that Guizhi Fuling Capsules has fewer adverse reactions and is relatively safe. This study provides a basis for studying ADR of Guizhi Fuling Capsules, and guidance for drug vigilance and risk management of Guizhi Fuling Capsules.

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20181219.001DOI Listing

Publication Analysis

Top Keywords

guizhi fuling
32
fuling capsules
32
adverse reactions
12
early warning
12
warning signals
12
500 adverse
8
guizhi
8
fuling
8
capsules
8
propensity score
8

Similar Publications

Composition analysis and mechanism of Guizhi Fuling capsule in anti-cisplatin-resistant ovarian cancer.

Transl Oncol

December 2024

Department of Pathogenic Biology, College of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China. Electronic address:

Objective: Cisplatin is the main chemotherapy drug for advanced ovarian cancer, but drug resistance often occurs. The aim of this study is to explore the molecular mechanism by which Guizhi Fuling capsule inhibits cisplatin resistance in ovarian cancer.

Methods: First, differences in cisplatin resistance, PA2G4 gene expression, migration, and invasion in A2780 cells and A2780/DDP cells were analyzed by qRT-PCR, scratch assay, transwell, immunofluorescence, and western blotting.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates Guizhi Fuling Formula (GFF) and α-adrenergic receptors (α-AR) using a novel method involving Colicin L7 DNase (CL7) and its immune protein (Im7) for immobilizing α-AR to a column.
  • The immobilization resulted in a stable α-AR column, facilitating the screening of active compounds in GFF, leading to the identification of paeoniflorin, cinnamic acid, and paeonol.
  • Notably, cinnamic acid and paeonol bind to the same site on α-AR as the drug tamsulosin, demonstrating the potential of this method for rapid analysis of functional compounds from
View Article and Find Full Text PDF

Background: Endometriosis (EMs) is a common chronic inflammatory gynecological disease that belongs to the classification of Traditional Chinese Medicine Syndromes "Zheng Jia," and the classic Chinese formula Guizhi Fuling (GZFL) demonstrates significant clinical efficacy in the treatment of this condition. This study aims to investigate GZFL's effect and potential mechanism in EMs.

Methods: The search reviewed randomized controlled trials in 7 databases from inception to 2024, assessed quality with the Cochrane tool, and analyzed data with STATA 15 by 2 reviewers.

View Article and Find Full Text PDF

The crucial component(s) of Guizhi Fuling Wan in inhibiting endometriosis development.

J Ethnopharmacol

February 2025

Department of Obstetrics and Gynecology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan; Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Electronic address:

Ethnopharmacological Relevance: Endometriosis is a common gynecological disorder that manifests as chronic pelvic pain and subfertility. Guizhi Fuling Wan (GFW), which contains five herbs, was first described in Chinese canonical medicine to treat qi stagnation and circulation. Although the inhibition of endometriosis by GFW has been previously demonstrated, its efficacy could potentially be improved by adjusting the dose of each component.

View Article and Find Full Text PDF

The role of Guizhi Fuling Pill (GZFL) in the treatment of ischemic stroke (IS) is still controversial, and its pharmacological mechanism remains unclear. To evaluate the efficacy and potential pharmacological mechanisms of GZFL on IS, a comprehensive method integrating meta-analysis, network pharmacology, and molecular docking was employed. Eight electronic databases were searched from inception to November 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!